Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with triweekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC) (HERBIS-4A / OGSG 1105)

Atsushi Takeno, Youichi Makari, Shunji Endo, Jin Matsubara, Ryohei Kawabata, Naotoshi Sugimoto, Hirokazu Taniguchi, Kenichi Nagai, Shigeyuki Tamura, Junichi Nishijima, Shugo Ueda, Yutaka Kimura, Takao Tamura, Kenji Kobayashi, Hisato Kawakami, Kazumasa Fujitani, Daisuke Sakai, Toshio Shimokawa, Yukinori Kurokawa and Taroh Satoh　ASCO-GI 2018, San-Francisco , 18-20 Jan 2018